Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
Karyopharm (Nasdaq: KPTI) reported Q2 2026 revenue of $33.4M, including U.S. XPOVIO (selinexor) net product revenue of $30.8M. The company said an sNDA for selinexor plus ruxolitinib in myelofibrosis is planned for August under the Accelerated Approval pathway. It reaffirmed 2026 revenue guidance of $130M to $150M.
How this was made
The 30-second read
Why it matters
The key incremental trading information is FDA’s written feedback that SVR35 appears to qualify as a reasonably likely surrogate endpoint to support an sNDA, plus the company’s stated plan to submit in August and request Priority Review. The earnings update also reaffirms 2026 revenue guidance and reports Q2 revenue and XPOVIO net product revenue.
Market read
Traders can position around regulatory-pathway confirmation and the upcoming August sNDA submission, while also monitoring whether the reaffirmed 2026 revenue guidance and XPOVIO demand trends hold.
What to watch
The article does not quantify probability of FDA acceptance or Priority Review, and it highlights only planned catalysts (acceptance, Priority Review, SENTRY-2 60 mg topline) rather than new FDA decisions or new financial guidance beyond reaffirmation.
Background
Karyopharm is a commercial-stage oncology company with XPOVIO (selinexor) and multiple late-stage programs, including myelofibrosis where it is pursuing an Accelerated Approval sNDA for selinexor plus ruxolitinib.
Ticker impact
Karyopharm says it remains on track to submit an August sNDA for selinexor plus ruxolitinib in myelofibrosis under Accelerated Approval, seeking Priority Review.
Bias to upside into the submission window if FDA acceptance/Priority Review is confirmed; volatility likely around any regulatory feedback or trial-data interpretation.
The article provides concrete regulatory pathway details (FDA feedback that SVR35 qualifies as RLSE) plus a scheduled operational milestone (August sNDA submission) and reaffirmed 2026 revenue guidance tied to XPOVIO.
Market effects
Reinforces the commercial and regulatory momentum for selinexor-based combinations in hematologic oncology, potentially supporting sentiment toward other oncology programs using surrogate endpoints.
Limited direct regional read-through, but mentions expanding ex-U.S. access and royalties from international partners.
Global relevance is moderate via ex-U.S. approvals and partner royalty growth, but the primary trading driver is U.S. FDA pathway progress.
Counterpoint
Even with FDA feedback, Accelerated Approval still depends on the totality of evidence and confirmatory outcomes; the endometrial cancer Phase 3 miss could pressure capital allocation and sentiment.
Key entities
- companyKaryopharm Therapeutics Inc.
Subject of the article; reports Q2 2026 results and updates on myelofibrosis sNDA plans for selinexor plus ruxolitinib.
- regulatorU.S. Food and Drug Administration (FDA)
Provided written feedback that SVR35 may qualify as a reasonably likely surrogate endpoint for overall survival to support the sNDA.
- productXPOVIO (selinexor)
Commercial product whose U.S. net product revenue and guidance are central to the company’s financial outlook.
- clinical_programSENTRY trial (myelofibrosis)
Phase 3 program whose results were presented at ASCO and published in the Journal of Clinical Oncology, supporting the sNDA rationale.
